Dr Butterworth (March 2004 JRSM 1 ) describes how a relative of his was diagnosed as hypertensive and put on a succession of medicines with near disastrous consequences. This chain of events had nothing to do with the vogue for evidence-based medicine. Rather, it reflects the enormous difficulty of practising good and safe medicine in the era of effective but dangerous drugs. The proliferation of lifeprolonging as opposed to symptom-reducing drugs makes clinical medicine complex and time consuming-though no-one would guess this from the mass of guidelines and protocols and the devolution of traditional medical tasks to non-doctors, all based on a fundamentally faulty world view where everything is either right or wrong, good or bad, black or white. Such reductionist inanity now extends to assessments of massive hospitals or even the whole NHS.
It was not what clinical trials have told us about treating hypertension that poisoned Dr Butterworth's relative. Whether he met any standard criteria for hypertension requiring drug treatment is not clear. To treat consequent dizziness with another drug appears simply crass; life, however, is complex, and we do not know the patient's blood pressure at the time this decision was made. Undertreated as well as over-treated hypertension can cause dizziness. The wise old general practitioner who took him off all medications may well have saved this man, but for all we know has over the years missed the opportunity to prevent dozens of strokes by adopting a 'common sense' approach to the management of hypertension in the asymptomatic elderly. Common sense, like evidence-based medicine, should be used only when appropriate.
Thank goodness we live in the era of dangerous and powerful drugs. Though the public may think that brain surgeons or heart surgeons have the most challenging jobs in medicine, in future the most difficult tasks will be polypharmacy in the elderly with multiple medical problems, to achieve the best combination of wellbeing and longevity. To master those arts will require lifelong education, natural empathy and most importantly, time and desire to think before prescribing. It is not the concept of evidence-based medicine we need fear, it is that of immediately demonstrable value for money. ) of managing intracerebral haemorrhage (ICH) in a patient previously anticoagulated for a prosthetic heart valve will be familiar to many clinicians. Whilst re-anticoagulation would be current practice, this is based on perceptions that the benefits of thromboembolism prevention surpass the risks of re-haemorrhage. 2 Such decisions are prone to recall or availability bias, given the varying risks of valve thromboembolism and the fragmentary evidence base on risks of rebleeding with further antithrombotics/anticoagulants. Clinical trials are unlikely to resolve this dilemma, not least because of the difficulty of recruiting sufficient participants. Decision analysis presents an alternative solution-developing a framework in which to combine variations in multiple probabilities within a mathematical model. Such techniques allow examination of current practices where no consensus exists, using a range of values/scenarios to test the feasibility of the model. These techniques have already seen successful use in reexamining evidence-based guidelines and in assessing decision-making in atrial fibrillation and intracerebral haemorrhage. 3, 4 We are currently constructing a decision model to explore the dilemma faced by Shah and Dawson, testing the effects of using anticoagulants and antiplatelet agents in patients with mechanical valves and ICH. A key test of decision modelling outcomes is to review them against current practices, and it is noteworthy that recent case reports have highlighted the potential short-term use of antiplatelet agents such as aspirin and clopidogrel in place of immediate anticoagulation following cerebral bleeding. 5
